Adelaide And Meath Hospital

This site in Dublin, Ireland is focused on Neoplasms, with trials exploring new ways to treat and monitor a range of cancers. The research activity centers on improving survival outcomes, slowing disease progression, and assessing how well promising cancer therapies work in real-world patient groups.

• Studies in advanced tumors are evaluating whether new treatment approaches can improve progression-free survival and overall survival.
• Research in clear cell renal cancer is testing immune-based and targeted treatment combinations for effectiveness as a first-line option.
• Trials in metastatic castration-resistant prostate cancer are examining whether adding new therapies can extend survival and delay disease progression.
• Work in HRRm or HRD-positive cancer is assessing the response to olaparib and related targeted treatment strategies.

Overall, the Oncology/Haematology Clinical Trials Research Office is supporting studies that aim to refine cancer treatment choices, improve response rates, and better understand which therapies may benefit patients most.

Clinical trials at this hospital are investigating newer cancer treatments that combine immune-based and targeted therapies. The main focus is on finding more effective options for patients with difficult-to-treat cancers and measuring whether these approaches can improve survival and tumor control.

• Studies in clear cell renal cell carcinoma are comparing combination treatment strategies to identify better first-line care.
• Research in advanced tumors is evaluating treatment effectiveness through key survival outcomes.
• Trials for HRRm or HRD-positive cancers are testing whether targeted therapy can produce meaningful tumor responses.
• Additional work is looking at how pembrolizumab may support outcomes in broader cancer populations.

These studies help clarify how precision medicine and immunotherapy may be used to improve care for patients with cancer at Adelaide And Meath Hospital.

The site is also active in research on specific solid tumors, especially metastatic castration-resistant prostate cancer and clear cell renal cancer. These trials are designed to test whether adding new treatments can slow progression, extend life, and improve response to therapy.

• In prostate cancer, studies are examining survival outcomes and radiographic disease control.
• In renal cancer, researchers are assessing whether immune and targeted combinations improve first-line treatment results.
• Across both areas, the goal is to evaluate treatment effectiveness in patients with advanced disease.
• Some studies also explore whether biomarker-defined groups respond differently to therapy.

This work supports more personalized cancer care by identifying which treatments may offer the greatest benefit for patients with advanced neoplasms.

Another important theme at the site is the study of cancers defined by genetic features such as HRRm and HRD. These trials aim to determine whether patients with specific tumor biology respond better to targeted treatment, helping improve the precision of cancer care.

• Research is focused on HRRm or HRD-positive cancer to understand treatment response in biomarker-selected patients.
• Studies are evaluating objective response rate as a measure of anti-cancer activity.
• The research also supports better selection of therapies for patients with advanced or treatment-resistant disease.
• These efforts contribute to the broader field of oncology by linking tumor biology with treatment outcomes.

At Adelaide And Meath Hospital, this line of research is helping advance more individualized approaches to cancer treatment.